Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290147 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00290147 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 22 participants.
The verdict
NCT00290147, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.
Interventions
- BIOLOGICAL D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-01 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290147
The ClinicalTrials.gov registry entry for NCT00290147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which D1ME100 (dengue-1 premembrane/envelope DNA vaccine) is the first listed.
NCT00290147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290147 about?
NCT00290147 is a clinical study titled "Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine". The purpose of this study is to exame the safety of a DNA vaccine against dengue-1.
What is the current status of trial NCT00290147?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2006-01. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00290147?
The interventions under investigation include: D1ME100 (dengue-1 premembrane/envelope DNA vaccine) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00290147?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.